Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.
FT Edit: Access on iOS and web
。关于这个话题，同城约会提供了深入分析
Что думаешь? Оцени!。safew官方版本下载对此有专业解读
Последние новости